Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine in Treatment Resistant Depression (SIGNATURE)
NCT05870501Completed
- Sponsor
- King's College London
- Start
- Oct 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ketamine in treatment-resistant depression (TRD) (2 arms), sponsored by King's College London. Primary endpoint: Brain resting state functional magnetic resonance imaging (fMRI) connectivity. Started Oct 2021; status: completed.
02
Drugs
ketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT05870501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05870501.